The global multiplex assays market is on a clear growth trajectory, with a new industry report valuing it at US$6.8 billion in 2025 and forecasting a climb to US$12.4 billion by 2030. This represents a robust compound annual growth rate (CAGR) of 12.8% from 2026 to 2030. π
For investors and industry analysts, this signals a structurally growing sector, underpinned by the global shift toward precision medicine and more efficient diagnostic tools. Laboratories are increasingly moving away from singleplex testing to simultaneous multi-analyte testing, which reduces sample volume, costs, and turnaround timeβa fundamental driver of this market expansion.
Why is the Market Growing? π
Several key factors are fueling the demand for multiplex assays:
- Rising Burden of Chronic & Infectious Diseases: The need for comprehensive diagnostic panels is higher than ever.
- Precision Medicine Expansion: Growth in companion diagnostics requires assays that can detect multiple biomarkers simultaneously.
- Increased Biopharma R&D: Biomarker-driven drug development is heavily reliant on high-plex screening capabilities.
- Laboratory Automation: The push for efficiency is driving adoption of automated multiplex platforms.
Analyst Insight: While the headline CAGR is strong, the real opportunity lies in the software and data-analysis segment. Growing at an estimated 16.0% CAGR, this category is becoming the key differentiator as AI-enabled data interpretation transforms raw assay results into actionable clinical insights.
Key Market Data at a Glance π
| Metric | Value | Notes |
|---|---|---|
| Market Value (2025) | US$6.8 Billion | Baseline for forecast period |
| Market Value (2030) | US$12.4 Billion | Forecast target |
| CAGR (2026-2030) | 12.8% | Strong, steady growth expected |
| Largest Product Segment | Consumables (68% Share) | Assay kits, reagents, beads |
| Fastest-Growing Product | Software & Data Analysis | ~16.0% CAGR |
| Largest Assay Type | Protein Multiplex (42% Share) | Core of current market |
| Fastest-Growing Assay Type | Nucleic Acid Multiplex | ~14.5% CAGR |
| Largest Region (2025) | North America | ~34.0% of global demand |
| Fastest-Growing Region | Asia Pacific | ~15.5% CAGR |
Regional Highlights
- North America remains the largest market, but its growth is being outpaced by Asia Pacific, which is growing at a 15.5% CAGR.
- China is a key growth engine in APAC, driven by its expanding diagnostics and life-sciences manufacturing base.
- India is emerging as the fastest-growing single market globally, with a projected 16.9% CAGR, fueled by rapid research-infrastructure development.
π In-Depth Fundamental Analysis
| Company | Share Price | P/E Ratio | P/B Ratio | ROE | Operating Margin (OPM) | Revenue Growth |
|---|---|---|---|---|---|---|
| A (Agilent) | $151 | 29.76 | 5.78 | 20.97% | 25.56% | 8.10% |
| BDX (Becton,) | $185 | 31.96 | 2.06 | 6.61% | 15.73% | 5.40% |
| BIO (Bio-Rad) | $386 | 46.97 | 1.44 | 3.11% | 11.18% | -0.10% |
| DHR (Danaher) | $208 | 37.02 | 2.78 | 7.61% | 19.78% | 5.50% |
| QGEN (Qiagen) | $43 | 22.07 | 2.67 | 11.93% | 26.32% | 0.30% |
| QTRX (Quanterix) | $3 | 0.00 | 0.53 | -46.48% | -68.37% | 34.40% |
| RVTY (Revvity,) | $130 | 62.61 | 2.01 | 3.21% | 17.05% | 1.30% |
| TECH (Bio-Techne) | $72 | 62.44 | 5.36 | 9.03% | 27.87% | 1.30% |
| TMO (Thermo) | $614 | 33.09 | 4.31 | 13.51% | 18.75% | 10.50% |
Competitive Landscape & Outlook π§¬
The market is led by major life science and diagnostics players, including Thermo Fisher Scientific, Bio-Rad Laboratories, QIAGEN, and Danaher Corporation. Competition is centered on innovation in multiplexing capacity, detection sensitivity, and platform automation.
Actionable Takeaway: The data suggests that companies with a strong focus on AI-integrated data analysis and high-plex nucleic acid panels are best positioned to capture value in this market through 2030. While the overall market is growing, the shift toward more complex, higher-value platforms is the definitive trend to watch.
